OCUL Insider Trading Activity and SEC Form 4 Filings
OCUL insider trading summary
Over the past 12 months, insiders at Ocular Therapeutix, Inc (OCUL) reported 27 sales worth $2.9M by 7 insiders and 1 open-market purchase worth $461K by 1 insider on SEC Form 4. Net insider selling was $2.4M.
Latest OCUL insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Oct 8, 2026 | Todd Anderman | Chief Legal Officer | Sell | $87K (11,984 @ $7.29) |
| Oct 2, 2026 | Jeffrey S. Heier | Chief Scientific Officer | Sell | $77K (10,869 @ $7.05) |
| Oct 2, 2026 | Peter Kaiser | Chief Development Officer | Sell | $70K (9,990 @ $7.05) |
| Aug 31, 2026 | Donald Notman | Chief Operating Officer | Sell | $11K (1,099 @ $10.24) |
| Aug 24, 2026 | Sanjay Nayak | Chief Strategy Officer | Sell | $20K (1,897 @ $10.78) |
| Aug 24, 2026 | Jeffrey S. Heier | Chief Scientific Officer | Sell | $36K (3,296 @ $10.78) |
| Aug 24, 2026 | Peter Kaiser | Chief Development Officer | Sell | $33K (3,035 @ $10.77) |
| Aug 24, 2026 | Pravin Dugel | See Remarks | Sell | $233K (21,649 @ $10.77) |
| May 26, 2026 | Jeffrey S. Heier | Chief Scientific Officer | Sell | $25K (3,018 @ $8.20) |
| May 26, 2026 | Peter Kaiser | Chief Development Officer | Sell | $24K (2,967 @ $8.20) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.